Absci Corporation (ABSI)
ABSI trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/0001672688-26-000068-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABSI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001672688 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.8M |
| Net income | -$115.2M |
| Operating income | -$120.3M |
| Net margin | -4113.7% |
| Operating margin | -4297.0% |
| Revenue growth | -38.2% |
| Cash | $20.0M |
| Total assets | $216.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 461.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $13.4M cash; operating cash flow -$28.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 172,745,810 (2026-10-30); 150,371,531 a year earlier; 92,938,477 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Jose, California, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $933K, sold $132K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $304K | -$33.3M | -$29.5M | $13.4M | $61K | $1.5M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $318K | -$33.2M | -$27.6M | $107.9M | $150K | $1.6M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $215K | -$29.6M | -$26.3M | $8.6M | $413K | $1.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $650K | -$29.6M | -$29.2M | $20.0M | $873K | $2.8M | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | $378K | -$28.7M | -$25.0M | $9.5M | $1.3M | $2.8M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $593K | -$30.6M | -$16.9M | $38.0M | $2.0M | $4.1M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $1.2M | -$26.3M | -$21.8M | $47.0M | $2.5M | $4.8M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $665K | -$29.0M | -$17.0M | $41.2M | $4.0M | $4.5M | 10-K 2025-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 364 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -16.9% |
| 1 month | -7.1% |
| 3 months | -10.7% |
| Year to date | +142.1% |
| 1 year | +220.1% |
| From 52-week high | -30.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
| ICLR | ICON plc | $191.40 | -1.67% | $14.7B |
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
| IQV | IQVIA Holdings Inc. | $264.73 | -0.15% | $43.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier